Kaki Amir, Subahi Ahmed, Shokr Mohamed, Ibrahim Walid, Yassin Ahmed, Hasan Reema, Alraies M Chadi, Schreiber Theodore
Department of Interventional Cardiology, Wayne State University School of Medicine, Detroit Medical Center Heart Hospital, Detroit, MI.
Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI.
Ochsner J. 2019 Fall;19(3):248-251. doi: 10.31486/toj.18.0018.
The Impella 2.5 and Impella Cardiac Power (CP) devices (ABIOMED) are used to provide mechanical circulatory support for high-risk percutaneous coronary interventions or cardiogenic shock as a bridge to recovery or destination therapy. The Impella device has shown both efficacy and safety in patients presenting with cardiogenic shock. Performing clinical and hemodynamic assessments of patients presenting with cardiogenic shock is an important step to determine if mechanical circulatory support with an Impella device is indicated. A 62-year-old male presented with cardiogenic shock requiring Impella device support. Two days later, the patient developed incessant ventricular tachycardia. Transthoracic echocardiography showed that the Impella device had migrated out of the ventricular cavity. Once the position of the Impella device was adjusted, ventricular tachycardia immediately resolved. Our case emphasizes the importance of using imaging modalities such as transthoracic echocardiography to ensure correct positioning of an Impella device in the left ventricle to avoid complications.
Impella 2.5和Impella心脏动力(CP)装置(ABIOMED公司)用于为高风险经皮冠状动脉介入治疗或心源性休克患者提供机械循环支持,作为恢复或目标治疗的桥梁。Impella装置在出现心源性休克的患者中已显示出有效性和安全性。对心源性休克患者进行临床和血流动力学评估是确定是否需要使用Impella装置进行机械循环支持的重要步骤。一名62岁男性出现心源性休克,需要Impella装置支持。两天后,患者出现持续性室性心动过速。经胸超声心动图显示Impella装置已移出心室腔。一旦调整了Impella装置的位置,室性心动过速立即消失。我们的病例强调了使用经胸超声心动图等成像方式来确保Impella装置在左心室中正确定位以避免并发症的重要性。